| 4.88 -0.01 (-0.2%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.55 | 1-year : | 7.24 |
| Resists | First : | 5.61 | Second : | 6.19 |
| Pivot price | 5.28  |
|||
| Supports | First : | 4.67 | Second : | 3.88 |
| MAs | MA(5) : | 4.87 |
MA(20) : | 5.38 |
| MA(100) : | 5.03 |
MA(250) : | 3.17 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13 |
D(3) : | 11.3 |
| RSI | RSI(14): 36.2 |
|||
| 52-week | High : | 7.19 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANTX ] has closed above bottom band by 24.5%. Bollinger Bands are 36.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.96 - 4.98 | 4.98 - 5.01 |
| Low: | 4.65 - 4.68 | 4.68 - 4.7 |
| Close: | 4.84 - 4.89 | 4.89 - 4.93 |
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Tue, 22 Sep 2026
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX) - Seeking Alpha
Sun, 20 Sep 2026
AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to S&P Global BMI Index - marketscreener.com
Wed, 16 Sep 2026
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) - Business Wire
Wed, 16 Sep 2026
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate - simplywall.st
Wed, 16 Sep 2026
AN2 Therapeutics (ANTX) awards stock and options to its chief medical officer - Stock Titan
Fri, 11 Sep 2026
AN2 Therapeutics (ANTX) director sells 1,108 shares under preset plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 75.2 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 2,440 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.8 % |
| Return on Equity (ttm) | -50.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -4.65 |
| PEG Ratio | 0 |
| Price to Book value | 2.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|